📈 Apheresis Market Annual Review: Innovation, Consumables Demand & 2031 Revenue Outlook

1. Market Size & Revenue Forecast

As of 2022, the global Apheresis Market was valued at approximately USD 3.70 billion, with projections reaching USD 7.98 billion by 2031, reflecting a CAGR of about 9.1% over the period 2022–2031 . An alternative estimate places the 2024 market value at USD 3.99 billion, rising to USD 6.3 billion by 2031, with a higher CAGR of 12.6% .

Within the equipment sub‑segment, forecasts suggest growth from USD 2.90 billion in 2023 to USD 5.35 billion by 2030, at a CAGR near 9.2% . Meanwhile, a broader projection sees the equipment market growing from USD 4.11 billion in 2024 to USD 9.61 billion by 2032, at a CAGR of 11.2% . For consistency, assume the broader forecast: the overall apheresis industry may approach USD 8 billion by 2031, with consumables and devices driving parallel growth.

2. Device Innovation

Technological advancements are central to momentum in the devices segment, projected to be the fastest-growing product category in the market .

• Automation & Smart Integration: New machines integrate automation, real‑time monitoring, and AI‑based digital health platforms—offering improved precision, reduced operator dependency, and smoother procedure workflows .

• Portable & User‑Friendly Platforms: Manufacturers are launching compact, modular devices designed for blood centers and smaller clinics. For instance, Fresenius’s APRED system (2023) offers enhanced usability and faster processing speeds .

• Membrane Filtration Expansion: While centrifugation is currently dominant, membrane filtration platforms are advancing swiftly—offering minimal cell damage and sharper selectivity, especially relevant in LDL apheresis and immunotherapy .

Major players such as Terumo BCT, Fresenius Kabi, Haemonetics, Asahi Kasei, B. Braun, Mallinckrodt, and Nikkiso are at the forefront of R&D and strategic expansion globally.

Noteworthy advancements: FDA clearance in mid‑2023 for a new Terumo BCT platelet processing device that works using a single centrifugation cycle; and Fresenius‑Lupagen collaboration exploring cell and gene therapy collection methods .

3. Consumables Demand

Consumables—including single‑use kits, filters, tubing sets, and blood bags—accounted for ~72–80% of total market share in 2022–2024 . In the therapeutic apheresis segment the consumables sub‑segment also dominated revenues in 2023 and is projected to register the highest CAGR over time .

Key drivers: each procedure requires fresh sets of tubing, filters and bags to maintain sterility, minimize cross‑contamination and comply with safety regulations. Rising volumes of therapeutic plasma exchanges, leukapheresis and photopheresis boost recurring consumables demand .

As autoimmune disorders, neurological diseases, and hematological conditions rise globally, the need for consumables continues to escalate—especially in blood donation centers and hospital settings .

4. Diagnostics & Epidemiological Drivers

Several overarching trends are fueling both devices and consumables demand:

• Chronic and Autoimmune Disease Prevalence: Conditions such as sickle cell disease, multiple sclerosis, myasthenia gravis, leukemia, lymphoma, and others are increasing worldwide—propelling demand for plasmapheresis and leukapheresis operations .

• Aging Demographics: With a growing geriatric population, diseases requiring plasma-derived therapies and apheresis management become more widespread, especially in developed regions .

• Blood Donation Expansion: Rising need for plasma and platelets—driven by both red‑cell and component donations—supports growth of automated donor apheresis systems and consumables volumes .

5. Regional Trends & Market Dynamics

• North America remains the largest market region, capturing 31–35% of global revenue by 2022–2024. The growth is backed by advanced healthcare infrastructure, reimbursement schemes, and established blood collection networks .

• Asia‑Pacific is the fastest‑growing region, with forecast CAGRs of over 11%, led by expanding healthcare access, increasing chronic disease incidence, and government investments in plasma collection services .

• Other regions such as Latin America, Middle East & Africa and Europe also register moderate growth opportunities as infrastructure improves and demand for therapeutic apheresis widens.

6. Key Trends in Innovation & Strategy

• AI and Data Analytics are becoming integrated into advanced apheresis platforms, offering data-driven monitoring, real-time alerts and connection to electronic health record systems, improving operational efficiency and clinical safety .

• Sustainable & Eco‑Friendly Consumables: Some companies are exploring alternatives to DEHP‑containing plastics to lower donor risk and environmental impact—aligning with global healthcare sustainability trends .

• Mergers and Collaborations: Major firms continue pursuing partnerships to launch tailored cell‑and‑gene therapy collection products and expand distribution in emerging markets .

7. Summary & Strategic Outlook to 2031

By 2031, the overall apheresis market is likely to approach USD 8 billion, with devices growing faster than the broader average due to accelerating innovation and automation. Meanwhile, consumables will maintain high volume—accounting for roughly 70–80% of revenue, sustained by recurring procedure needs and expanding therapeutic apheresis usage.

• Device advances: smarter, portable, user-friendly systems will drive adoption in both hospital and donation settings.

• Consumables: recurring demand continues to scale with clinical volume; safety, sterility, and regulatory compliance remain drivers.

• Regional momentum: North America anchors the market; Asia‑Pacific and developing markets are rising rapidly.

• Applications: therapeutic plasma exchange remains dominant, while photopheresis and leukapheresis gain share in immune‑mediated and oncology‑related treatments.

📌 Final Takeaways

1. Innovation-led growth: Automation, AI, membrane tech and portable device form factors underpin rising device adoption.

2. Consumables dominance persists, due to procedure-based usage patterns and a broadening therapeutic base.

3. Sustained revenue growth: Expect high single‑digit to low‑teens CAGR, with overall market nearing USD 8 billion by 2031.

4. Strategic opportunities: sustainability, digital integration, and emerging market expansion are key investment themes.